MCCA
DNA icon

Mill Creek Capital Advisors’s Ginkgo Bioworks DNA Stock Holding History

Mill Creek Capital Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,103
Closed -$28.1K – 256
2024
Q2 		$28.1K Sell
2,103
-52
-2% -$1.55K ﹤0.01% 258
2024
Q1 		$100K Buy
2,155
+52
+2% +$2.69K ﹤0.01% 238
2023
Q4 		$142K Hold
2,103
– – ﹤0.01% 234
2023
Q3 		$152K Sell
2,103
-25
-1% -$2K 0.01% 219
2023
Q2 		$158K Buy
2,128
+25
+1% +$1.48K 0.01% 232
2023
Q1 		$112K Sell
2,103
-7
-0.3% -$444 ﹤0.01% 239
2022
Q4 		$143K Buy
+2,110
New +$194K 0.01% 219

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mill Creek Capital Advisors's DNA Position: Q3 2024 in Review

Mill Creek Capital Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 2,103 shares — an estimated $28.1K sold.

Mill Creek Capital Advisors first reported a position in DNA in Q4 2022 and held it in 7 quarters. The position peaked at $158K in Q2 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Mill Creek Capital Advisors reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Mill Creek Capital Advisors sold 2,103 Ginkgo Bioworks shares in Q3 2024, an estimated $28.1K.
  • Mill Creek Capital Advisors first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 7 quarters.
  • Mill Creek Capital Advisors's Ginkgo Bioworks position peaked at $158K in Q2 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Mill Creek Capital Advisors's 13F filing for Q3 2024, filed 6 Nov 2024.